Revolution Medicines, Inc. logo

Revolution Medicines, Inc. (RVMD) Q1 2026 Earnings

RVMD·Reported May 6, 2026·After market close

Diluted EPS came in at $-2.29 (-102.7% YoY), missed the $-1.83 consensus by $0.46. Revolution Medicines, Inc. reports across 1 business segment, led by RAS(ON) Inhibitors.

Diluted EPS
$-2.29missed by $0.46
Consensus: $-1.83
SEC

SEC Filings

Earnings release8-K · 0001193125-26-208918
Quarterly report10-Q · 0001193125-26-208969

Financial Snapshot

Trailing eight quarters through Q1 2026

View all metrics

Revenue

View metric

Net Income

View metric

EPS (Diluted)

View metric

Q1 2026 Earnings FAQ

Common questions about Revolution Medicines, Inc.'s Q1 2026 earnings report.

Revolution Medicines, Inc. (RVMD) reported Q1 2026 earnings on May 6, 2026 after market close.

Revolution Medicines, Inc. reported diluted EPS of $-2.29 for Q1 2026.

EPS missed the consensus estimate of $-1.83 by $0.46.

Compared to the same quarter a year prior, diluted EPS declined 102.7% from $-1.13.

You can read the 8-K earnings release (0001193125-26-208918) and the 10-Q periodic report (0001193125-26-208969) directly on SEC EDGAR. The filing index links above go to sec.gov.